查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1446453

照護現場市場規模、佔有率和趨勢分析報告：按產品、最終用途、地區和細分市場預測，2024-2030 年

Point Of Care Diagnostics Market Size, Share & Trends Analysis Report By Product (Infectious Diseases, Glucose Testing, Cardiac Markers), By End-use (Clinics, Home, Hospitals), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 295 Pages | 商品交期: 2-10個工作天內

價格

照護現場(POT) 診斷市場成長與趨勢：

Grand View Research, Inc.的最新報告顯示，預計2030年全球照護現場診斷市場規模將達到685億美元，2024年至2030年複合年成長率為6.1%。

遠端保健POCT 等先進技術的引入預計將推動市場成長。此外，不斷成長的老年人口和對居家照護的需求預計將推動市場的發展。

POCT 在非洲和拉丁美洲等新興國家的採用預計將成為全球 POCT 市場成長的決定因素。當局正在分散醫療保健系統並增加投資。例如，肯亞的非洲法規為託管設備服務計劃撥款 346.7 美元，作為政府透過採購新設備實現設施現代化的努力的一部分。衛生署選擇 GE Health 和飛利浦向 47 個國家提供設備。同樣，拉丁美洲體外診斷檢測的分散化，尤其是感染疾病的分散化，鼓勵私營公司採取戰略舉措，以滿足該地區對可負擔得起的 POCT 的現有需求。我鼓勵這樣做。

目前正在開發的 POC 設備和測試用於各種醫療診斷應用，包括癌症、懷孕和感染疾病。患者和醫生使用 POC 測試來篩檢病理、確認診斷並根據患者的健康狀況設計適當的治療方法。然而，包括醫生、患者和看護者在內的消費者的熱情差異很大。 POC診斷產品的這種動態消費模式也是由於缺乏經濟擴充性、經濟效益和全民健保結構所造成的。

鑑於 COVID-19，世界各地實施了封鎖，需要進行虛擬就診和快速診斷測試，以幫助患者避免去醫院就診。封鎖後，電子醫療策略已成為新的優先和投資領域，包括自動病患預約系統、測試結果傳輸系統、醫護人員通訊系統以及企業和政府的醫療產品採購系統。即使在大流行之後，居家醫療預計仍將是一個優先事項，特別是對於患有既往疾病的患者而言。例如，Neurometrics指定了一個團隊來開發DPNCheck業務，這是一種針對週邊神經病變的POCT。該團隊負責擴大公司在醫療保健市場的足跡，並專注於 Medicare Advantage 人群。

照護現場(POT) 診斷市場報告亮點：

  • 感染疾病主導市場，2023年佔全球銷售佔有率的27.8%。該行業的成長是由快速檢測需求不斷成長推動的，這促使行業參與者向分散地區提供現場護理解決方案並引入創新解決方案。
  • 由於為家庭患者提供的照護現場診斷的舒適性和成本效益，預計家庭產業在預測期內將呈現最高成長率。 POCT 設備易於使用，不需要現代化的實驗室基礎設施即可輕鬆測試患者樣本中的目標分析物。
  • 北美市場佔據主導地位，2023 年佔 42.9% 的佔有率。這是由於對新技術、大量關鍵參與者和先進醫療基礎設施的需求增加。
  • 由於癌症、糖尿病、心血管疾病和感染疾病的上升，亞太地區預計將出現顯著的市場成長。可支配收入有限的人口不斷成長，是該地區主要參與者的潛在目標市場。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章照護現場診斷市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場問題分析
    • 市場機會分析
  • 照護現場診斷市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
  • 按產品分類的價格分析
    • 血糖測試
    • Hb1Ac 測試
    • 血液凝固檢驗
    • 不孕/懷孕
    • 感染疾病
    • HIV POC
    • 困難梭狀芽孢桿菌POC
    • HBV POC
    • 肺炎或鏈球菌相關感染疾病
    • 呼吸道融合細胞病毒(RSV) POC
    • HPV POC
    • 流感/流感 POC
    • HCV POC
    • MRSA POC
    • 結核病和抗藥性結核病的 POC
    • HSV POC
    • COVID-19
    • 其他感染疾病
    • 心臟標記
    • 甲狀腺刺激素
    • 血液學
    • 基層醫療系統
    • 分散式臨床化學
    • 屎
    • 血脂測試
    • 癌症標記物
    • 血氣/電解質
    • 門診化學
    • 濫用藥物 (DOA) 測試
    • 自體免疫疾病
    • 尿液檢查/腎臟病學

第4章照護現場診斷市場：產品評估與趨勢分析

  • 2023年及2030年產品市場佔有率
  • 細分儀表板
  • 按產品分類的全球照護現場診斷市場展望
  • 2018年至2030年市場規模、預測與趨勢分析

第5章照護現場診斷市場：最終用途估計與趨勢分析

  • 2023 年及 2030 年最終用途市場佔有率
  • 細分儀表板
  • 按最終用途分類的全球照護現場診斷市場前景
  • 2018年至2030年市場規模、預測與趨勢分析

第6章照護現場診斷市場：區域估計與趨勢分析

  • 2023 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 2018-2030年市場規模及預測趨勢分析：
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商形勢
    • List of key distributors and channel partners
    • Key customers
    • Key company market share analysis, 2023
    • Company Profiles
    • Company Market Positioning Analysis, 2023
    • Key Parameters
    • Market Differentiators
    • Private Companies
    • Regional Mapping：Public and Private Companies

第8章 結論

Product Code: 978-1-68038-046-0

Point Of Care Diagnostics Market Growth & Trends:

The global point of care diagnostics market size is expected to reach USD 68.5 billion by 2030, registering a CAGR of 6.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. The introduction of advanced technologies such as Telehealth enabled POCT is expected to fuel market growth. Furthermore, the rise in the geriatric population and their need for accessible home-based care are anticipated to drive the market.

The adoption of POCT in emerging economies such as Africa and Latin America is anticipated to be a growth determinant of the global POCT market. The authorities are decentralizing the healthcare system and increasing their investments. For instance, the African regulations in Kenya allotted USD 346.7 to Managed Equipment Services project for the government's initiative toward modernizing facilities by procuring new equipment. The Ministry of Health selected GE Health and Philips to offer equipment across 47 countries. Similarly, Latin America decentralized IVD testing, which encourages private players to take strategic initiatives to meet the region's existing demand for affordable POCT, especially in the infectious diseases segment.

Currently developed POC devices and tests are employed across different medical diagnostic applications, including cancer, pregnancy, and infectious diseases. Patients and physicians employ POC tests to screen conditions, confirm diagnoses, and design suitable therapeutic approaches based on patient health. However, the enthusiasm displayed by different consumers, such as doctors, patients, and caregivers, varies widely. This dynamic consumption pattern of POC diagnostic products is also attributed to economic scalability, financial interests, and lack of a universal healthcare structure.

In the light of COVID-19, the lockdown imposed across the globe has necessitated virtual visits and rapid diagnostic tests that assist patients to avoid hospital visits. Post-lockdown, the eHealth strategy is the emerging area of priority and investment such as an automated patient appointment system, lab result transmission system, healthcare workers' communication system, and medical products procurement system for the companies and governments. It is anticipated to continue to prioritize home-based healthcare delivery even after the pandemic, especially for patients with pre-existing conditions. For instance, NeuroMetrix, Inc. appointed a team to develop the business of DPNCheck, a POCT for peripheral neuropathies. The team is responsible for expanding the footprint in the healthcare market and focusing on the Medicare Advantage population.

Point Of Care Diagnostics Market Report Highlights:

  • The Infectious disease led the market and accounted for 27.8% of global revenue share in 2023. Growth of the segment is attributed to increasing demand for rapid tests, which has encouraged industry players to deliver point of care solutions to decentralized regions and launch innovative solutions.
  • Home sector is projected to witness the highest growth rate over the forecast period owing to the comfort level and cost-effectiveness of point of care diagnostics provided to patients at home. POCT devices are easy to use and do not, mandatorily, require any modern lab infrastructure for testing simpler target analytes in a patient's sample
  • North America dominated the market and accounted for a 42.9% share in 2023 owing to the increasing demand for new technologies, a large pool of key players, and advanced healthcare infrastructure
  • The Asia Pacific is anticipated to witness significant growth in the market owing to the rising prevalence of cancer, diabetes, cardiovascular diseases, and infectious diseases. The increasing population with limited disposable income is the potential target market for the key players in the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. End Use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Point Of Care Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Introduction of CLIA waived tests
      • 3.2.1.2. Rise in funding from government and private institutions
      • 3.2.1.3. Growing geriatric population base
      • 3.2.1.4. Growing prevalence of target diseases
      • 3.2.1.5. Growing demand for home healthcare and the introduction of advance technology enabled products
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High procedure costs coupled with limited adoption of POC devices in certain emerging regions
      • 3.2.2.2. Presence of ambiguous regulatory as well as reimbursement frame work for primary care setting
    • 3.2.3. Market challenge analysis
      • 3.2.3.1. POC device pose challenges in maintaining the quality standards
    • 3.2.4. Market opportunity analysis
      • 3.2.4.1. Networking & remote integration of POC diagnostics products
        • 3.2.4.1.1. Smartphone orientation
        • 3.2.4.1.2. Embedded vision based solutions
        • 3.2.4.1.3. Digital technologies
  • 3.3. Point Of Care Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. Pricing Analysis, By Product
    • 3.4.1. Glucose Testing
    • 3.4.2. Hb1Ac Testing
    • 3.4.3. Coagulation Testing
    • 3.4.4. Fertility/Pregnancy
    • 3.4.5. Infectious Disease
    • 3.4.6. HIV POC
    • 3.4.7. Clostridium Difficile POC
    • 3.4.8. HBV POC
    • 3.4.9. Pneumonia or Streptococcus Associated Infections
    • 3.4.10. Respiratory Syncytial Virus (RSV) POC
    • 3.4.11. HPV POC
    • 3.4.12. Influenza/Flu POC
    • 3.4.13. HCV POC
    • 3.4.14. MRSA POC
    • 3.4.15. TB and Drug-resistant TB POC
    • 3.4.16. HSV POC
    • 3.4.17. COVID-19
    • 3.4.18. Other Infectious Diseases
    • 3.4.19. Cardiac Markers
    • 3.4.20. Thyroid Stimulating Hormone
    • 3.4.21. Hematology
    • 3.4.22. Primary Care Systems
    • 3.4.23. Decentralized Clinical Chemistry
    • 3.4.24. Feces
    • 3.4.25. Lipid Testing
    • 3.4.26. Cancer Marker
    • 3.4.27. Blood Gas/Electrolytes
    • 3.4.28. Ambulatory Chemistry
    • 3.4.29. Drug of Abuse (DOA) Testing
    • 3.4.30. Autoimmune Diseases
    • 3.4.31. Urinalysis/Nephrology

Chapter 4. Point Of Care Diagnostics Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Point Of Care Diagnostics Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Glucose Testing
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.2. Hb1Ac Testing
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.3. Coagulation Testing
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.4. Fertility/Pregnancy Testing
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.5. Infectious Disease
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.5.2. HIV POC
        • 4.4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.5.3. Clostridium Difficile POC
        • 4.4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.5.4. HBV POC
        • 4.4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.5.5. Pneumonia or Streptococcus Associated Infections
        • 4.4.5.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.5.6. Respiratory Syncytial Virus (RSV) POC
        • 4.4.5.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.5.7. HPV POC
        • 4.4.5.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.5.8. Influenza/Flu POC
        • 4.4.5.8.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.5.9. HCV POC
        • 4.4.5.9.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.5.10. MRSA POC
        • 4.4.5.10.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.5.11. TB and drug resistant TB POC
        • 4.4.5.11.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.5.12. HSV POC
        • 4.4.5.12.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.5.13. COVID-19
        • 4.4.5.13.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.5.14. Other infectious diseases
        • 4.4.5.14.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.6. Cardiac Markers
      • 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.7. Thyroid Stimulating Hormone
      • 4.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.8. Hematology
      • 4.4.8.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.9. Primary Care Systems
      • 4.4.9.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.10. Decentralized Clinical Chemistry
      • 4.4.10.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.11. Feces
      • 4.4.11.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.12. Lipid Testing
      • 4.4.12.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.13. Cancer Marker
      • 4.4.13.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.14. Blood Gas/Electrolytes
      • 4.4.14.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.15. Ambulatory Chemistry
      • 4.4.15.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.16. Drug of Abuse (DOA) Testing
      • 4.4.16.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.17. Autoimmune diseases
      • 4.4.17.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.18. Urinalysis/Nephrology
      • 4.4.18.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Point Of Care Diagnostics Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Point Of Care Diagnostics Market by End Use Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Clinics
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD billion)
      • 5.4.1.2. Pharmacy & Retail Clinics
        • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 5.4.1.3. Physician Office
        • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 5.4.1.4. Urgent Care Clinics
        • 5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 5.4.1.5. Non-practice Clinics
        • 5.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.2. Hospitals
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.3. Home
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.4. Assisted Living Healthcare Facilitates
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.5. Laboratory
      • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Point Of Care Diagnostics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2023 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6. Europe
    • 6.6.1. Germany
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.2. UK
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.6. Russia
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Russia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.7. Norway
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/ reimbursement structure
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.8. Sweden
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/ reimbursement structure
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.9. Denmark
      • 6.6.9.1. Key country dynamics
      • 6.6.9.2. Regulatory framework/ reimbursement structure
      • 6.6.9.3. Competitive scenario
      • 6.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.7.4. South Korea
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.7.5. Australia
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/ reimbursement structure
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/ reimbursement structure
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.8.2. Mexico
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.8.3. Argentina
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/ reimbursement structure
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework/ reimbursement structure
      • 6.9.1.3. Competitive scenario
      • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/ reimbursement structure
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/ reimbursement structure
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/ reimbursement structure
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
      • 7.3.1.1. Abbott
      • 7.3.1.2. Alere Inc.
      • 7.3.1.3. F. Hoffmann-La Roche Ltd.
      • 7.3.1.4. Siemens Healthcare GmbH
      • 7.3.1.5. Danaher Corporation
      • 7.3.1.6. Werfen
      • 7.3.1.7. BD
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. Company Profiles
      • 7.3.4.1. F. Hoffmann-La Roche Ltd.
        • 7.3.4.1.1. Company overview
        • 7.3.4.1.2. Financial performance
        • 7.3.4.1.3. Product benchmarking
        • 7.3.4.1.4. Strategic initiatives
      • 7.3.4.2. Qiagen
        • 7.3.4.2.1. Company overview
        • 7.3.4.2.2. Financial performance
        • 7.3.4.2.3. Product benchmarking
        • 7.3.4.2.4. Strategic initiatives
      • 7.3.4.3. Danaher Corporation
        • 7.3.4.3.1. Company overview
        • 7.3.4.3.2. Financial performance
        • 7.3.4.3.3. Product benchmarking
        • 7.3.4.3.4. Strategic initiatives
      • 7.3.4.4. Becton Dickinson (BD)
        • 7.3.4.4.1. Company overview
        • 7.3.4.4.2. Financial performance
        • 7.3.4.4.3. Product benchmarking
        • 7.3.4.4.4. Strategic initiatives
      • 7.3.4.5. bioMerieux
        • 7.3.4.5.1. Company overview
        • 7.3.4.5.2. Financial performance
        • 7.3.4.5.3. Product benchmarking
        • 7.3.4.5.4. Strategic initiatives
      • 7.3.4.6. Abbott
        • 7.3.4.6.1. Company overview
        • 7.3.4.6.2. Financial performance
        • 7.3.4.6.3. Product benchmarking
        • 7.3.4.6.4. Strategic initiatives
      • 7.3.4.7. Siemens Healthcare GmbH
        • 7.3.4.7.1. Company overview
        • 7.3.4.7.2. Financial performance
        • 7.3.4.7.3. Product benchmarking
        • 7.3.4.7.4. Strategic initiatives
      • 7.3.4.8. Werfen
        • 7.3.4.8.1. Company overview
        • 7.3.4.8.2. Financial performance
        • 7.3.4.8.3. Product benchmarking
        • 7.3.4.8.4. Strategic initiatives
      • 7.3.4.9. Nova Biomedical
        • 7.3.4.9.1. Company overview
        • 7.3.4.9.2. Financial performance
        • 7.3.4.9.3. Product benchmarking
        • 7.3.4.9.4. Strategic initiatives
      • 7.3.4.10. Trividia Health, Inc.
        • 7.3.4.10.1. Company overview
        • 7.3.4.10.2. Financial performance
        • 7.3.4.10.3. Product benchmarking
        • 7.3.4.10.4. Strategic initiatives
      • 7.3.4.11. QuidelOrtho Corporation
        • 7.3.4.11.1. Company overview
        • 7.3.4.11.2. Financial performance
        • 7.3.4.11.3. Product benchmarking
        • 7.3.4.11.4. Strategic initiatives
      • 7.3.4.12. Trinity Biotech
        • 7.3.4.12.1. Company overview
        • 7.3.4.12.2. Financial performance
        • 7.3.4.12.3. Product benchmarking
        • 7.3.4.12.4. Strategic initiatives
      • 7.3.4.13. Sekisui Diagnostics
        • 7.3.4.13.1. Company overview
        • 7.3.4.13.2. Financial performance
        • 7.3.4.13.3. Product benchmarking
        • 7.3.4.13.4. Strategic initiatives
      • 7.3.4.14. Orasure Technologies, Inc.
        • 7.3.4.14.1. Company overview
        • 7.3.4.14.2. Financial performance
        • 7.3.4.14.3. Product benchmarking
        • 7.3.4.14.4. Strategic initiatives
      • 7.3.4.15. Spectral Medical, Inc.
        • 7.3.4.15.1. Company overview
        • 7.3.4.15.2. Financial performance
        • 7.3.4.15.3. Product benchmarking
        • 7.3.4.15.4. Strategic initiatives
      • 7.3.4.16. EKF Diagnostics Holdings plc.
        • 7.3.4.16.1. Company overview
        • 7.3.4.16.2. Financial performance
        • 7.3.4.16.3. Product benchmarking
        • 7.3.4.16.4. Strategic initiatives
      • 7.3.4.17. Anbio Biotechnology Co., Ltd.
        • 7.3.4.17.1. Company overview
        • 7.3.4.17.2. Financial performance
        • 7.3.4.17.3. Product benchmarking
        • 7.3.4.17.4. Strategic initiatives
      • 7.3.4.18. AccuBioTech Co., Ltd.
        • 7.3.4.18.1. Company overview
        • 7.3.4.18.2. Financial performance
        • 7.3.4.18.3. Product benchmarking
        • 7.3.4.18.4. Strategic initiatives
      • 7.3.4.19. ALPHA LABORATORIES
        • 7.3.4.19.1. Company overview
        • 7.3.4.19.2. Financial performance
        • 7.3.4.19.3. Product benchmarking
        • 7.3.4.19.4. Strategic initiatives
    • 7.3.5. Company Market Positioning Analysis, 2023
      • 7.3.5.1. Glucose Monitoring
      • 7.3.5.2. Cardiac Markers
      • 7.3.5.3. Hematology
      • 7.3.5.4. Coagulation
      • 7.3.5.5. Fertility Testing
      • 7.3.5.6. Infectious Diseases
      • 7.3.5.7. Decentralized Clinical Chemistry
      • 7.3.5.8. Oncology Markers
      • 7.3.5.9. Blood Gas Testing
      • 7.3.5.10. Ambulatory Testing
      • 7.3.5.11. Drug of Abuse
      • 7.3.5.12. Urinalysis
    • 7.3.6. Key Parameters
      • 7.3.6.1. Company Size
      • 7.3.6.2. Geographic Presence
      • 7.3.6.3. Production Portfolio
      • 7.3.6.4. Collaborations
    • 7.3.7. Market Differentiators
      • 7.3.7.1. Application Trends
      • 7.3.7.2. Technology Trends
      • 7.3.7.3. Test Location Trends
      • 7.3.7.4. End-use Trends
      • 7.3.7.5. Regional Trends
    • 7.3.8. Private Companies
      • 7.3.8.1. New Entrants/Emerging Players
    • 7.3.9. Regional Mapping: Public and Private Companies

Chapter 8. Conclusion

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America point of care diagnostics market, by region, 2018 - 2030 (USD Billion)
  • Table 3 North America point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 4 North America point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 5 U.S. point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 6 U.S. point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 7 Canada point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 8 Canada point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 9 Europe point of care diagnostics market, by region, 2018 - 2030 (USD Billion)
  • Table 10 Europe point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 11 Europe point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 12 Germany point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 13 Germany point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 14 UK point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 15 UK point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 16 France point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 17 France point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 18 Italy point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 19 Italy point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 20 Spain point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 21 Spain point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 22 Russia point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 23 Russia point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 24 Denmark point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 25 Denmark point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 26 Sweden point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 27 Sweden point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 28 Norway point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 29 Norway point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 30 Asia Pacific point of care diagnostics market, by region, 2018 - 2030 (USD Billion)
  • Table 31 Asia Pacific point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 32 Asia Pacific point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 33 China point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 34 China point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 35 Japan point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 36 Japan point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 37 India point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 38 India point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 39 South Korea point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 40 South Korea point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 41 Australia point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 42 Australia point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 43 Thailand point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 44 Thailand point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 45 Latin America point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 46 Latin America point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 47 Brazil point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 48 Brazil point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 49 Mexico point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 50 Mexico point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 51 Argentina point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 52 Argentina point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 53 MEA point of care diagnostics market, by region, 2018 - 2030 (USD Billion)
  • Table 54 MEA point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 55 MEA point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 56 South Africa point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 57 South Africa point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 58 Saudi Arabia point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 59 Saudi Arabia point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 60 UAE point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 61 UAE point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 62 Kuwait point of care diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 63 Kuwait point of care diagnostics market, by end use, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Point of care diagnostics market: market outlook
  • Fig. 14 Point of care diagnostics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Point of care diagnostics market driver impact
  • Fig. 20 Point of care diagnostics market restraint impact
  • Fig. 21 Point of care diagnostics market strategic initiatives analysis
  • Fig. 22 Point of care diagnostics market: Product movement analysis
  • Fig. 23 Point of care diagnostics market: Product outlook and key takeaways
  • Fig. 24 Glucose testing market estimates and forecast, 2018 - 2030
  • Fig. 25 Hb1Ac testing market estimates and forecast, 2018 - 2030
  • Fig. 26 Coagulation testing market estimates and forecast, 2018 - 2030
  • Fig. 27 Fertility/pregnancy market estimates and forecast, 2018 - 2030
  • Fig. 28 Infectious disease market estimates and forecast, 2018 - 2030
  • Fig. 29 HIV POC market estimates and forecast, 2018 - 2030
  • Fig. 30 Pneumonia or streptococcus associated infections market estimates and forecasts, 2018 - 2030
  • Fig. 31 Respiratory syncytial virus (RSV) POC market estimates and forecasts, 2018 - 2030
  • Fig. 32 HPV POC market estimates and forecasts, 2018 - 2030
  • Fig. 33 Influenza/ flu POC market estimates and forecasts, 2018 - 2030
  • Fig. 34 HCV POC market estimates and forecasts, 2018 - 2030
  • Fig. 35 MRSA POC market estimates and forecasts, 2018 - 2030
  • Fig. 36 TB and drug resistant TB POC market estimates and forecasts, 2018 - 2030
  • Fig. 37 HSV POC market estimates and forecasts, 2018 - 2030
  • Fig. 38 COVID-19 market estimates and forecasts, 2018 - 2030
  • Fig. 39 Other infectious diseases estimates and forecasts, 2018 - 2030
  • Fig. 40 Cardiac markers market estimates and forecasts, 2018 - 2030
  • Fig. 41 Thyroid stimulating hormone market estimates and forecasts, 2018 - 2030
  • Fig. 42 Hematology market estimates and forecasts, 2018 - 2030
  • Fig. 43 Primary care systems estimates and forecasts, 2018 - 2030
  • Fig. 44 Decentralized clinical chemistry market estimates and forecasts, 2018 - 2030
  • Fig. 45 Feces market estimates and forecasts, 2018 - 2030
  • Fig. 46 Lipid testing market estimates and forecasts, 2018 - 2030
  • Fig. 47 Cancer marker estimates and forecasts, 2018 - 2030
  • Fig. 48 Blood gas/ electrolytes market estimates and forecasts, 2018 - 2030
  • Fig. 49 Ambulatory chemistry market estimates and forecasts, 2018 - 2030
  • Fig. 50 Drug of abuse (DoA) testing market estimates and forecasts, 2018 - 2030
  • Fig. 51 Autoimmune diseases market estimates and forecasts, 2018 - 2030
  • Fig. 52 Urinalysis/nephrology market estimates and forecasts, 2018 - 2030
  • Fig. 53 Point of care diagnostics market: end use movement analysis
  • Fig. 54 Point of care diagnostics market: end use outlook and key takeaways
  • Fig. 55 Clinics market estimates and forecasts, 2018 - 2030
  • Fig. 56 Pharmacy & retail clinics market estimates and forecasts, 2018 - 2030
  • Fig. 57 Physician office market estimates and forecasts, 2018 - 2030
  • Fig. 58 Urgent care clinics market estimates and forecasts, 2018 - 2030
  • Fig. 59 Non-practice clinics market estimates and forecasts, 2018 - 2030
  • Fig. 60 Hospitals market estimates and forecasts, 2018 - 2030
  • Fig. 61 Home market estimates and forecasts, 2018 - 2030
  • Fig. 62 Assisted living healthcare facilities market estimates and forecasts, 2018 - 2030
  • Fig. 63 Laboratory market estimates and forecasts, 2018 - 2030
  • Fig. 64 Global point of care diagnostics market: Regional movement analysis
  • Fig. 65 Global point of care diagnostics market: Regional outlook and key takeaways
  • Fig. 66 Global point of care diagnostics market share and leading players
  • Fig. 67 North America market share and leading players
  • Fig. 68 Europe market share and leading players
  • Fig. 69 Asia Pacific market share and leading players
  • Fig. 70 Latin America market share and leading players
  • Fig. 71 Middle East & Africa market share and leading players
  • Fig. 72 North America: SWOT
  • Fig. 73 Europe SWOT
  • Fig. 74 Asia Pacific SWOT
  • Fig. 75 Latin America SWOT
  • Fig. 76 MEA SWOT
  • Fig. 77 North America, by country
  • Fig. 78 North America
  • Fig. 79 North America market estimates and forecasts, 2018 - 2030
  • Fig. 80 U.S. key country dynamics
  • Fig. 81 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 82 Canada country dynamics
  • Fig. 83 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 84 Europe
  • Fig. 85 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 86 UK country dynamics
  • Fig. 87 UK market estimates and forecasts, 2018 - 2030
  • Fig. 88 Germany country dynamics
  • Fig. 89 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 90 France country dynamics
  • Fig. 91 France market estimates and forecasts, 2018 - 2030
  • Fig. 92 Italy country dynamics
  • Fig. 93 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 94 Spain country dynamics
  • Fig. 95 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 96 Russia country dynamics
  • Fig. 97 Russia market estimates and forecasts, 2018 - 2030
  • Fig. 98 Denmark country dynamics
  • Fig. 99 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 100 Sweden country dynamics
  • Fig. 101 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 102 Norway country dynamics
  • Fig. 103 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 104 Asia Pacific
  • Fig. 105 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 106 China country dynamics
  • Fig. 107 China market estimates and forecasts, 2018 - 2030
  • Fig. 108 Japan country dynamics
  • Fig. 109 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 110 India country dynamics
  • Fig. 111 India market estimates and forecasts, 2018 - 2030
  • Fig. 112 Thailand country dynamics
  • Fig. 113 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 114 South Korea country dynamics
  • Fig. 115 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 116 Australia country dynamics
  • Fig. 117 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 118 Latin America
  • Fig. 119 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 120 Brazil country dynamics
  • Fig. 121 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 122 Mexico country dynamics
  • Fig. 123 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 124 Argentina country dynamics
  • Fig. 125 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 126 Middle East and Africa
  • Fig. 127 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 128 South Africa country dynamics
  • Fig. 129 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 130 Saudi Arabia country dynamics
  • Fig. 131 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 132 UAE country dynamics
  • Fig. 133 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 134 Kuwait country dynamics
  • Fig. 135 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 136 Market share of key market players- Point of care diagnostics market